Trial reportScience translational medicine2021
Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals.
Open access · greenAbstract readRandomized Controlled Trial
In one paragraph
Trial report in Science translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 186 papers, 7 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
186citing papers in PubMed, 7 pooled it
38.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
186 citing papers in PubMed, 7 syntheses or guidelines pooled it, 337 citations in OpenAlex.
- Polish Recommendations for the Early Detection of Type 1 Diabetes in the Pediatric Population: A Position Statement of the Polish Society of Pediatric Endocrinology and Diabetology and the Pediatric Section of the Diabetes Poland 2026.Hormone research in paediatrics · 2026Guideline
- Immunomodulatory interventions in type 1 diabetes: a systematic review and meta-analysis revealing paradoxical dissociation between beta-cell preservation and glycemic control.BMC endocrine disorders · 2025Pooled it
- UK best practice recommendations for children and young people <18 years with pre-stage 3 type 1 diabetes, on behalf of the British Society for Paediatric Endocrinology and Diabetes (BSPED).Diabetic medicine : a journal of the British Diabetic Association · 2025Guideline
- Harnessing Machine Learning, a Subset of Artificial Intelligence, for Early Detection and Diagnosis of Type 1 Diabetes: A Systematic Review.International journal of molecular sciences · 2025Pooled it
- Anti-CD3 monoclonal antibody in treating patients with type 1 diabetes: an updated systematic review and meta-analysis.Cardiovascular diabetology · 2025Pooled it
- Pediatric Endocrine Society Statement on Considerations for Use of Teplizumab (Tzield™) in Clinical Practice.Hormone research in paediatrics · 2025Guideline
- ISPAD Clinical Practice Consensus Guidelines 2024: Screening, Staging, and Strategies to Preserve Beta-Cell Function in Children and Adolescents with Type 1 Diabetes.Hormone research in paediatrics · 2024Guideline
- Novel Approach for Assessing Outcomes of Type 1 Diabetes Prevention Trials Over a Fixed Time Interval.Diabetes · 2025Trial
- Trajectory of beta cell function and insulin clearance in stage 2 type 1 diabetes: natural history and response to teplizumab.Diabetologia · 2025Trial
- Teplizumab induces persistent changes in the antigen-specific repertoire in individuals at risk for type 1 diabetes.The Journal of clinical investigation · 2024Trial
- Comparisons of Metabolic Measures to Predict T1D vs Detect a Preventive Treatment Effect in High-Risk Individuals.The Journal of clinical endocrinology and metabolism · 2024Trial
- A randomized trial of oral gamma aminobutyric acid (GABA) or the combination of GABA with glutamic acid decarboxylase (GAD) on pancreatic islet endocrine function in children with newly diagnosed type 1 diabetes.Nature communications · 2022Trial
- The Deterrence of Rapid Metabolic Decline Within 3 Months After Teplizumab Treatment in Individuals at High Risk for Type 1 Diabetes.Diabetes · 2021Trial
- Predicting future risk of type 1 and type 2 diabetes after gestational diabetes mellitus using polygenic scores: a cohort study.Diabetologia · 2026Article
- GLP1-E2 therapy delays autoimmune diabetes in late-stage prediabetic NOD mice and potentiates low-dose anti-CD3 therapy for enhanced disease protection.Diabetologia · 2026Article
- From Disposal to Display: Crinophagy as a β-Cell Source of Neoantigens in Type 1 Diabetes.Immunological reviews · 2026Review
- Reducing Diabetic Ketoacidosis in Pediatric Type 1 Diabetes: The Impact of Screening Programs and Early Disease-Modifying Treatment.Journal of clinical medicine · 2026Review
- Considerations for the clinical use of teplizumab in stage 2 Type 1 diabetes: A Consensus Statement from the British Society of Paediatric Endocrinology and Diabetes (BSPED) and the Association of British Clinical Diabetologists (ABCD).Diabetic medicine : a journal of the British Diabetic Association · 2026Article
- Accounting for Age-Related Increases in HbA1c More Accurately Quantifies Risk of Type 1 Diabetes Progression in Islet Autoantibody-Positive Adults.Diabetes care · 2026Observational
- Special Issue-Diabetes Mellitus: Current Research and Future Perspectives, 2nd Edition.Journal of personalized medicine · 2026Article
126 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 7 institutions in 1 country.
Emily K SimsDepartment of Pediatrics, Indiana University School of Medicine, Indianapolis, IN 46202, USA.ORCID 0000-0002-4393-954X
Brian N BundyDepartment of Epidemiology, and Pediatrics University of South Florida, Tampa, FL 33612, USA.ORCID 0000-0003-3478-714X
Kenneth StierDepartments of Immunobiology and Internal Medicine, Yale University, New Haven, CT 06520, USA.ORCID 0000-0003-4735-6314
Elisavet SertiImmune Tolerance Network, Bethesda, MD 20814, USA.
Noha LimImmune Tolerance Network, Bethesda, MD 20814, USA.
S Alice LongBenaroya Research Institute, Seattle WA 98101, USA.ORCID 0000-0002-0281-1240
Susan M GeyerMayo Clinic, Rochester, MN 55905, USA.
Antoinette MoranDepartment of Pediatrics, University of Minnesota, Minneapolis, MN 55455, USA.ORCID 0000-0002-2694-5147
Carla J GreenbaumBenaroya Research Institute, Seattle WA 98101, USA.ORCID 0000-0003-4451-9800
Carmella Evans-MolinaDepartment of Pediatrics, Indiana University School of Medicine, Indianapolis, IN 46202, USA.ORCID 0000-0001-7764-8663
Kevan C HeroldDepartments of Immunobiology and Internal Medicine, Yale University, New Haven, CT 06520, USA. kevan.herold@yale.edu.ORCID 0000-0003-1534-6613
Type 1 Diabetes TrialNet Study Group
Yale University · USBenaroya Research InstituteImmune Tolerance Network · USIndiana University School of MedicineMayo Clinic in Arizona · USUniversity of Minnesota · USUniversity of South Florida · US
Funding
Immune Tolerance NetworkUM1AI109565 · NIAID · BENAROYA RESEARCH INST AT VIRGINIA MASON · 2022 to 2025
$94.0MData Coordinating Center for Type 1 Diabetes TrialNetU01DK106993 · NIDDK · UNIVERSITY OF SOUTH FLORIDA · 2022 to 2025
$43.4MYale Diabetes Research CenterP30DK045735 · YALE UNIVERSITY · 1993 to 2025
$10.2MInterferon Signaling in the T1D Islet MicroenvironmentU01DK127786 · UNIVERSITY OF CHICAGO · 2025 to 2025
$3.5MType I Diabetes Trialnet at StsnfordU01DK061042 · STANFORD UNIVERSITY · 2001 to 2005
$2.1MType 1 Diabetes TrialNet Clinical Network HubU01DK103282 · NIDDK · BENAROYA RESEARCH INST AT VIRGINIA MASON · 2022 to 2025
$2.1MNorthwest Clinical Center for Type 1 Diabetes - TrialNetU01DK061034 · BENAROYA RESEARCH INST AT VIRGINIA MASON · 2001 to 2005
$2.1MTranslation CoreP30DK097512 · INDIANA UNIVERSITY INDIANAPOLIS · 2025 to 2025
$1.7MPrediction and Prevention of Type I DiabetesU01DK061058 · CHILDREN'S HOSP PITTSBURGH/UPMC HLTH SYS · 2001 to 2005
$1.2MUCSF TrialNet: A Phase II Trial of hokT3gamma1 (Ala-Ala)U01DK061010 · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · 2001 to 2005
$1.2Mβ cell miRNAs Function as Molecular Hubs of Type 1 Diabetes PathogenesisR01DK127308 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI Carmella Evans-Molina · 2022 to 2022
$427kBeta cell extracellular vesicles in health and diseaseR01DK121929 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI Emily K Sims · 2023 to 2023
$391kNIAID NIH HHS R01 AI141952NIAID NIH HHS UM1 AI109565NIDDK NIH HHS P30 DK045735NIDDK NIH HHS P30 DK097512NIDDK NIH HHS R01 DK093954NIDDK NIH HHS R01 DK121929NIDDK NIH HHS R01 DK127308NIDDK NIH HHS U01 DK061010NIDDK NIH HHS U01 DK061034NIDDK NIH HHS U01 DK061042NIDDK NIH HHS U01 DK061058NIDDK NIH HHS U01 DK085453NIDDK NIH HHS U01 DK085461NIDDK NIH HHS U01 DK085465NIDDK NIH HHS U01 DK085466NIDDK NIH HHS U01 DK085476NIDDK NIH HHS U01 DK085499NIDDK NIH HHS U01 DK085504NIDDK NIH HHS U01 DK085509NIDDK NIH HHS U01 DK103153NIDDK NIH HHS U01 DK103180NIDDK NIH HHS U01 DK103266NIDDK NIH HHS U01 DK103282NIDDK NIH HHS U01 DK106984NIDDK NIH HHS U01 DK106993NIDDK NIH HHS U01 DK106994NIDDK NIH HHS U01 DK107013NIDDK NIH HHS U01 DK107014NIDDK NIH HHS U01 DK127786NIDDK NIH HHS UC4 DK106993NIDDK NIH HHS UC4 DK117009
Abstract
We analyzed the effects of a single 14-day course of teplizumab treatment on metabolic function and immune cells among participants in a previously reported randomized controlled trial of nondiabetic relatives at high risk for type 1 diabetes (T1D). In an extended follow-up (923-day median) of a previous report of teplizumab treatment, we found that the median times to diagnosis were 59.6 and 27.1 months for teplizumab- and placebo-treated participants, respectively (HR = 0.457,
Indexed as
CD8-Positive T-LymphocytesDiabetes Mellitus, Type 1Antibodies, Monoclonal, HumanizedC-PeptideHumansInsulinAntibodies, Monoclonal, HumanizedC-PeptideInsulinteplizumab
Identifiers
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.